TRS 010
Alternative Names: TRS-010Latest Information Update: 03 Mar 2022
At a glance
- Originator Zhejiang Teruisi Pharmaceutical
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Hypercholesterolaemia
Most Recent Events
- 02 Mar 2022 Investigation of TRS 010 in Hypercholesterolaemia is ongoing in China (Parenteral) (Zhejiang Teruisi Pharmaceutical pipeline, March 2022)